Biological Collection of Kidney Cells (CRHiPS)
Primary Purpose
Pseudoxanthoma Elasticum
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
urine collection
Sponsored by
About this trial
This is an interventional basic science trial for Pseudoxanthoma Elasticum focused on measuring PXE, renal cells, urine, calcification, omics, drug screening
Eligibility Criteria
Inclusion Criteria:
- Patient with PXE diagnosed on clinical and histological criteria, according to current guidelines
- Patient aged over 18
- Patient informed, having understood the purpose and means of the study and signed the consent of participation
- Patient affiliated to the French social welfare system
Exclusion Criteria:
- Pregnant or nursing PXE woman
- Patient under guardianship, deprived of liberty by court or administrative decision, hospitalized without consent or admitted to a health or social institution for purposes other than research
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
PXE patients
Arm Description
urine collection and culture of renal cells
Outcomes
Primary Outcome Measures
Urine collection
Three urine samples in each PXE in-patient consequences of the functional deficiency of the ABCC6 transporter involved in the pathophysiology of PXE
Secondary Outcome Measures
Isolation and culture of renal cells
According to the routine procedure of our lab
Impact of ABCC6 mutations on renal cell functions
Proteomic and metabolomic and RNAseq approaches
High throughput screening of drugs to restore ABCC6 function in PXE patients renal cells
Evaluation of PPi release and other relevant readouts
Full Information
NCT ID
NCT03364504
First Posted
July 11, 2017
Last Updated
December 5, 2017
Sponsor
University Hospital, Angers
Collaborators
Université de Nantes, Hungarian Academy of Sciences
1. Study Identification
Unique Protocol Identification Number
NCT03364504
Brief Title
Biological Collection of Kidney Cells
Acronym
CRHiPS
Official Title
Biological Collection of Renal Cells for the Functional Study of the ABCC6 Transporter on iPS-derived Hepatocytes and Renal Cells
Study Type
Interventional
2. Study Status
Record Verification Date
June 2017
Overall Recruitment Status
Unknown status
Study Start Date
January 2018 (Anticipated)
Primary Completion Date
August 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Angers
Collaborators
Université de Nantes, Hungarian Academy of Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Our objective is to obtain human induced pluripotent stem cells from urine samples of PXE patients for further proteomic and metabolomic studies and treatment screening.
Detailed Description
Pseudoxanthoma elasticum (PXE) is a genetic multysystem disorder with cutaneous, ophtalmological and cardiovascular involvement.
PXE is associated with mutations of ABCC6 gene coding for the membrane transporter ABCC6 protein. This transporter is normally expressed in hepatocytes and epithelial cells of renal proximal convoluted tubules.
Thus, PXE could be regarded as a metabolic disease of hepatic and renal origin, with clinical and biological involvement/consequences for remote organs.
The substance transported by ABCC6 protein being still unknown, ethiological PXE treatment does not exist yet. However, ABCC6 deficiency is associated with low level of blood PPi (pyrophosphate), which is natural inhibitor of calcium-phosphate deposition.
The aim of the project is to obtain the renal cells derived from PXE patients for their further usage in proteomic and metabolomic studies, as well as for screening of treatment modalities aimed to correct ABCC6 functional deficiency.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pseudoxanthoma Elasticum
Keywords
PXE, renal cells, urine, calcification, omics, drug screening
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PXE patients
Arm Type
Experimental
Arm Description
urine collection and culture of renal cells
Intervention Type
Other
Intervention Name(s)
urine collection
Intervention Description
3 urine collections during 24 hours
Primary Outcome Measure Information:
Title
Urine collection
Description
Three urine samples in each PXE in-patient consequences of the functional deficiency of the ABCC6 transporter involved in the pathophysiology of PXE
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Isolation and culture of renal cells
Description
According to the routine procedure of our lab
Time Frame
8 weeks
Title
Impact of ABCC6 mutations on renal cell functions
Description
Proteomic and metabolomic and RNAseq approaches
Time Frame
3 months
Title
High throughput screening of drugs to restore ABCC6 function in PXE patients renal cells
Description
Evaluation of PPi release and other relevant readouts
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with PXE diagnosed on clinical and histological criteria, according to current guidelines
Patient aged over 18
Patient informed, having understood the purpose and means of the study and signed the consent of participation
Patient affiliated to the French social welfare system
Exclusion Criteria:
Pregnant or nursing PXE woman
Patient under guardianship, deprived of liberty by court or administrative decision, hospitalized without consent or admitted to a health or social institution for purposes other than research
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
26586530
Citation
Si-Tayeb K, Idriss S, Champon B, Caillaud A, Pichelin M, Arnaud L, Lemarchand P, Le May C, Zibara K, Cariou B. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. Dis Model Mech. 2016 Jan;9(1):81-90. doi: 10.1242/dmm.022277. Epub 2015 Nov 19.
Results Reference
result
PubMed Identifier
15894595
Citation
Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A. Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J Med Genet. 2005 Dec;42(12):881-92. doi: 10.1136/jmg.2004.030171. Epub 2005 May 13.
Results Reference
result
PubMed Identifier
24969777
Citation
Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Varadi A, Plomp A, Bergen AA, Oude Elferink RP, Borst P, van de Wetering K. ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1985-9. doi: 10.1161/ATVBAHA.114.304017. Epub 2014 Jun 26.
Results Reference
result
PubMed Identifier
24277820
Citation
Jansen RS, Kucukosmanoglu A, de Haas M, Sapthu S, Otero JA, Hegman IE, Bergen AA, Gorgels TG, Borst P, van de Wetering K. ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20206-11. doi: 10.1073/pnas.1319582110. Epub 2013 Nov 25.
Results Reference
result
Learn more about this trial
Biological Collection of Kidney Cells
We'll reach out to this number within 24 hrs